Skip to main content
Aptabio Therapeutics Inc. logo

Aptabio Therapeutics Inc. — Investor Relations & Filings

Ticker · 293780 ISIN · KR7293780003 KO Manufacturing
Open in API
Filings indexed 209 across all filing types
Latest filing 2023-03-20 Director's Dealing
Country KR South Korea
Listing KO 293780

About Aptabio Therapeutics Inc.

https://aptabio.com/

Aptabio Therapeutics Inc. is a biopharmaceutical company dedicated to developing first-in-class drugs for intractable diseases with high unmet medical needs. The company's research is driven by proprietary platform technologies. One core platform focuses on regulating oxidative stress through selective NOX (NADPH oxidase) inhibitors, targeting the root causes of inflammation and fibrosis to treat diabetic complications, vascular diseases, and neurodegenerative disorders. A second platform centers on the regulation of cancer-associated fibroblasts (CAF) to overcome resistance and enhance the efficacy of immuno-oncology therapies for difficult-to-treat cancers. By leveraging these distinct approaches, Aptabio aims to discover and advance novel therapeutic candidates for challenging medical conditions.

Recent filings

Filing Released Lang Actions
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the acquisition of shares by the CEO (Lee Soo Jin) of Aptabio Co., Ltd. In the context of financial reporting, filings regarding personal share transactions by company directors and executives are classified as 'Director's Dealing'.
2023-03-20 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Aptabio Co., Ltd. It contains the agenda for the upcoming Annual General Meeting (AGM), including items such as financial statement approval, board remuneration, and director activities. This document is a standard proxy statement/notice sent to shareholders to inform them of the meeting and solicit their participation/votes. In the provided taxonomy, this fits best under 'Proxy Solicitation & Information Statement' (PSI).
2023-03-15 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company scheduled its AGM on a date that coincides with other companies' meetings, citing auditor schedules and board availability. Since this is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or the results, it falls under the general regulatory filing category.
2023-03-15 Korean
투자판단관련주요경영사항(조영제유발급성신장손상(CI-AKI) 치료제 Isuzinaxib(APX-115)의 국내 2상 임상시험계획(IND) 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KIND) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It specifically details the submission of an Investigational New Drug (IND) application for a Phase 2 clinical trial. Since this is a specific regulatory disclosure of a material event (clinical trial progress) rather than a general report announcement, a financial report, or a legal proceeding, it falls under the 'Regulatory Filings' category as the most appropriate classification for miscellaneous corporate disclosures.
2023-02-24 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Aptabio) regarding a significant change in financial structure (revenue or profit/loss change of 30% or more). This is a standard regulatory disclosure requirement in the Korean market (DART system) for listed companies to report material financial changes before the final audit report is finalized. Since it is a specific regulatory disclosure of financial performance highlights rather than a full annual report or a simple announcement of a report's publication, it falls under the 'Earnings Release' category as it provides the initial financial highlights for the period. FY 2022
2023-01-31 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company Aptabio. It outlines the date, location, and the agenda items (such as financial statement approval, director compensation, and amendments to the articles of incorporation) to be voted upon. This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2023-01-31 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.